Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab SC vs IV preference in NSCLC
NCT05171777Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Percentage of Participants Who Preferred Atezolizumab SC to Atezolizumab IV Assessed Using Patient Preference Questionnaire at 18 weeks. Started Apr 2022; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05171777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171777.